FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093184367> ?p ?o ?g. }

• W2093184367 endingPage "1626" @default.
• W2093184367 startingPage "1618" @default.
• W2093184367 abstract "Cytosine arabinoside (AraC) is rapidly inactivated via systemic deamination with half-lives ranging from 1 h (i.v.) to 4 h (s.c.) – and cannot be applied orally due to its hydrophilic properties. These limitations might be overcome by YNK01 – a lipophilic prodrug of AraC – that is resistant to deoxycytidine deaminase and can be applied orally. In the present study the therapeutic activity, side-effects and pharmacokinetics of YNK01 were evaluated in a phase I/II study including patients with relapsed or refractory acute myeloid leukemia (AML) (n = 23) or low-grade non-Hodgkin’s lymphoma (NHL) (n = 20). YNK01 was given by 14 day cycles with escalating doses starting with a daily dose of 50 mg/m2 (equivalent to 20 mg/m2 AraC on a molar basis). The maximum tolerated dose was reached at the 600 mg/m2 dose level with WHO grade 3–4 diarrhoea as the main toxicity. In the 23 patients with AML two complete remissions, four partial remissions and three patients with stable disease were observed. In the 23 patients with AML two complete remissions, four partial remissions and three patients with NHL two cases reached partial remission and six other patients mainained stable disease. Pharmacokinetic evaluations were performed during 34 treatment cycles in 28 patients. The data suggest that YNK01 was absorbed in the distal part of the small intestine and taken up into hepatocytes. After hepatic ϕ and subsequent β-oxydation of YNK01 the released AraC (and its deamination product AraU) appeared in the systemic circulation. Time of maximum concentration (h), half-life (h) and area under the curve (ng·h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66). Of the total dose of YNK01 15.8% was absorbed and metabolized to AraC and AraU, defining the metabolic bioavailability of this prodrug. A linear relationship was observed between YNK01 dose and YNK01 AUC and AraC AUC over the whole dose range tested. AraC was released from hepatocytes over a prolonged period of time resulting in long lasting plasma levels similar to a continuous i.v. infusion. After administration of YNK01 at a dosage of 100–150 mg/m2 plasma levels of AraC were comparable to those achieved after low-dose AraC treatment (20 mg/m2) while at doses of YNK01 of 450–600 mg/m2 concentrations of standard-dose AraC (100 mg/m2) were obtained. We conclude that YNK01 shows considerable activity against relapsed and refractory AML and NHL and that its pharmacokinetic properties offers advantages in comparison to (standard) i.v. or s.c. AraC in clinical practice." @default.
• W2093184367 created "2016-06-24" @default.
• W2093184367 creator A5004056411 @default.
• W2093184367 creator A5005594026 @default.
• W2093184367 creator A5033935778 @default.
• W2093184367 creator A5037807649 @default.
• W2093184367 creator A5048388170 @default.
• W2093184367 creator A5062688084 @default.
• W2093184367 creator A5064112838 @default.
• W2093184367 creator A5067544820 @default.
• W2093184367 creator A5072021108 @default.
• W2093184367 date "1998-10-01" @default.
• W2093184367 modified "2023-10-17" @default.
• W2093184367 title "Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin’s lymphoma – phase I/II studies and pharmacokinetics" @default.
• W2093184367 cites W1519562949 @default.
• W2093184367 cites W1550823476 @default.
• W2093184367 cites W1563567966 @default.
• W2093184367 cites W1586763410 @default.
• W2093184367 cites W1623357808 @default.
• W2093184367 cites W1964193296 @default.
• W2093184367 cites W2033902902 @default.
• W2093184367 cites W2034152763 @default.
• W2093184367 cites W2044866537 @default.
• W2093184367 cites W2057407177 @default.
• W2093184367 cites W2083667219 @default.
• W2093184367 cites W2094764170 @default.
• W2093184367 cites W2141877307 @default.
• W2093184367 cites W2314807339 @default.
• W2093184367 cites W2318674152 @default.
• W2093184367 cites W2334170117 @default.
• W2093184367 cites W2395492256 @default.
• W2093184367 cites W2397640124 @default.
• W2093184367 cites W2402115735 @default.
• W2093184367 cites W2411299539 @default.
• W2093184367 cites W2413341750 @default.
• W2093184367 cites W2414540868 @default.
• W2093184367 cites W2415499162 @default.
• W2093184367 cites W2416330842 @default.
• W2093184367 cites W2416636853 @default.
• W2093184367 cites W2417782824 @default.
• W2093184367 cites W2418555281 @default.
• W2093184367 cites W2421799037 @default.
• W2093184367 cites W2431019304 @default.
• W2093184367 cites W2433989702 @default.
• W2093184367 cites W2463748194 @default.
• W2093184367 cites W29987246 @default.
• W2093184367 cites W3721018 @default.
• W2093184367 cites W1651358555 @default.
• W2093184367 doi "https://doi.org/10.1038/sj.leu.2401152" @default.
• W2093184367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9766508" @default.
• W2093184367 hasPublicationYear "1998" @default.
• W2093184367 type Work @default.
• W2093184367 sameAs 2093184367 @default.
• W2093184367 citedByCount "29" @default.
• W2093184367 countsByYear W20931843672013 @default.
• W2093184367 countsByYear W20931843672015 @default.
• W2093184367 countsByYear W20931843672016 @default.
• W2093184367 countsByYear W20931843672018 @default.
• W2093184367 countsByYear W20931843672021 @default.
• W2093184367 countsByYear W20931843672022 @default.
• W2093184367 countsByYear W20931843672023 @default.
• W2093184367 crossrefType "journal-article" @default.
• W2093184367 hasAuthorship W2093184367A5004056411 @default.
• W2093184367 hasAuthorship W2093184367A5005594026 @default.
• W2093184367 hasAuthorship W2093184367A5033935778 @default.
• W2093184367 hasAuthorship W2093184367A5037807649 @default.
• W2093184367 hasAuthorship W2093184367A5048388170 @default.
• W2093184367 hasAuthorship W2093184367A5062688084 @default.
• W2093184367 hasAuthorship W2093184367A5064112838 @default.
• W2093184367 hasAuthorship W2093184367A5067544820 @default.
• W2093184367 hasAuthorship W2093184367A5072021108 @default.
• W2093184367 hasBestOaLocation W20931843671 @default.
• W2093184367 hasConcept C108215921 @default.
• W2093184367 hasConcept C112705442 @default.
• W2093184367 hasConcept C126322002 @default.
• W2093184367 hasConcept C145782189 @default.
• W2093184367 hasConcept C181199279 @default.
• W2093184367 hasConcept C185592680 @default.
• W2093184367 hasConcept C2776694085 @default.
• W2093184367 hasConcept C2777844706 @default.
• W2093184367 hasConcept C2778041864 @default.
• W2093184367 hasConcept C2778461978 @default.
• W2093184367 hasConcept C2778729363 @default.
• W2093184367 hasConcept C2778822529 @default.
• W2093184367 hasConcept C2779338263 @default.
• W2093184367 hasConcept C2780258809 @default.
• W2093184367 hasConcept C29730261 @default.
• W2093184367 hasConcept C31760486 @default.
• W2093184367 hasConcept C55493867 @default.
• W2093184367 hasConcept C71924100 @default.
• W2093184367 hasConcept C90924648 @default.
• W2093184367 hasConcept C98274493 @default.
• W2093184367 hasConceptScore W2093184367C108215921 @default.
• W2093184367 hasConceptScore W2093184367C112705442 @default.
• W2093184367 hasConceptScore W2093184367C126322002 @default.
• W2093184367 hasConceptScore W2093184367C145782189 @default.
• W2093184367 hasConceptScore W2093184367C181199279 @default.
• W2093184367 hasConceptScore W2093184367C185592680 @default.

• next